Showing results (61-70 of 121) with videos related to

Sort By:
Pageof 13
Leukemia|August 10, 2011
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemiaF Damm, T Bunke, F Thol, et al.
Leukemia|April 12, 2016
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarateA Chaturvedi, M M Araujo Cruz, N Jyotsana, et al.
Scientific Reports|September 8, 2023
Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemiaR F Schlenk, D Weber, J Krzykalla, et al.
Leukemia|February 1, 2017
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failureM Wattad, D Weber, K Döhner, et al.
Leukemia|June 24, 2017
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaV I Gaidzik, D Weber, P Paschka, et al.
Leukemia|May 4, 2016
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresV I Gaidzik, V Teleanu, E Papaemmanuil, et al.
Leukemia|November 25, 2016
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesisF Thol, S Klesse, L Köhler, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 13, 2010
Comprehensive microRNA expression profiling of the hematopoietic hierarchyO I Petriv, F Kuchenbauer, A D Delaney, et al.
Leukemia|February 6, 2016
GFI1 as a novel prognostic and therapeutic factor for AML/MDSJ M Hönes, L Botezatu, A Helness, et al.
Leukemia|February 8, 2019
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidineR F Schlenk, D Weber, W Herr, et al.
Pageof 13